axd121

Adam P. Dicker, MD, PhD, FASTRO

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 503-0013 fax

Most Recent Peer-reviewed Publications

  1. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle
  2. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy
  3. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology
  4. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
  5. PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
  6. Utilizing 10-Year Results From the American Board of Radiology Clinical Examination to Identify Areas for Programmatic Improvement
  7. Common error pathways seen in the RO-ILS data that demonstrate opportunities for improving treatment safety
  8. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer
  9. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  10. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704
  11. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
  12. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  13. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities
  14. Phase i Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with Concurrent Radiotherapy for Advanced Head and Neck Cancer
  15. Ensuring sample quality for blood biomarker studies in clinical trials: A multicenter international study for plasma and serum sample preparation
  16. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
  17. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer the NRG oncology rtog 0436 phase 3 randomized clinical trial
  18. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839
  19. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
  20. Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics